Objective To analyze the effect of budesonide on the level of chemokin-like factor-1 (CKLF-1) and immune function in children with acute asthma induced by infection. Methods The clinical data of 100 cases of acute attack of infection-induced asthma treated in our hospital from March 2015 to May 2018 were selected for analysis, and were divided into two. The control group received routine treatment. The observation group was given with budesonide on the basis of the control group, and the clinical efficacy of the two groups of patients after treatment was analyzed. Results The scores of daytime and nighttime symptoms in the observation group were lower than those in the control group and the number of acute attacks was lower than those in the control group within 6 weeks and 12 weeks, and the difference was statistically significant (t=23.276,20.732,53.137,48.590,12.514,P<0.001).There were no statistically significant difference in levels of inflammatory cytokines, T-lymphocyte subsets and pulmonary function levels between the two groups before treatment (t=0.097,0.020,0.251,1.299,1.301,0.272,0.151,0.208,0.100,0.294,P＞0.05). After treatment, the levels of interferon (IFN-γ), T lymphocyte subsets, forced expiratory volume in 1 second (FEV1), vital capacity (VC), FEV1 percentage of expected value (FEV1 %), and the levels of forced vital capacity (FVC) were higher in the observation group observation group than the control group, chemotaxis sample factor 1 (CKLF-1), tumor necrosis factor alpha (TNF-α), interleukin 4 (IL-4) level were lower than those in the control group (t=3.940,7.707,7.740,3.909,5.289,17.220,3.885,6.932,5.028,19.941,17.665,P＜0.01). Conclusion The treatment of budesonide in children with acute attack of infection-induced asthma can reduce the IL-4 level of CKLF-1TNF-α, increase the level IFN-γ in patients, and effectively improve the clinical symptoms, lung function and immune function of children.